The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
NCT Number: NCT06886113
Cardiogenic shock a serious complication of a heart attack (myocardial infarction). Despite evaluation of several new treatments during the last decade, the mortality in patients with cardiogenic shock still exceeds 50%. An alternative to current management is restoration of the volume of blood pumped by the heart (cardiac output) using a ventricular assist device. In the acute setting this is difficult but can be done using the CorVad device which is a catheter-based, axial flow pump that pumps blood directly from the left ventricle into the circulation thereby restoring blood flow to the failing organs. The hypothesis of the current study is to reduce mortality and morbidity of patients with cardiogenic shock using the CorVad device. The study will be carried out as a randomized multicenter study where eligible patients will be randomized to receive conventional circulatory support or support with the CorVad device and inotropic support if needed. A total of 269 patients are planned
Trial opening soon.
Get Notified18 year–80 year
All sexes
Interventional
Not applicable
Hangzhou, Zhejiang, 310000, China
The study is a prospective, multicenter trial in patients with AMICS randomized 1:1 to CorVad or current guideline-driven therapy with planned enrollment of 269 patients. Patients comatose after out of hospital cardiac arrest are excluded. Eligible patients are randomized immediately following shock diagnosis. Among patients randomized to receive CorVad, the device is placed prior to angioplasty. The primary endpoint is all-cause mortality at 180 days.The target population of subjects are patients with acute myocardial infarction with cardiogenic shock who need high-risk PCI treatment, and sign an informed consent form (ICF) approved by the Ethics Committee (EC). Subjects who meet the enrolment criteria as judged by the investigator will apply the trial product according to the requirements and will be followed up to 180 days after the procedure.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
peripheral signs of tissue hypoperfusion (arterial blood lactate ≥2.5mmol/l and/or SvO2 <55% with a normal PaO2) and systolic blood pressure less than 100mmHg and/or need for vasopressor therapy (dopamine/ norepinephrine or epinephrine), and
Exclusion criteria
Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs
Control group treated with Impella CP for a minimum of 48 hrs
Time frame: up to 6 months
Death from all causes
Time frame: minimum follow-up 6 months
Major cardiovascular and cerebrovascular events, death, cardiac transplant, escalation to permanent left ventricular assist device, re-hospitalization for heart failure
Time frame: up to 6 months
Rate of major bleeding, vascular complications, and significant hemolysis
Time frame: up to 6 months
Days alive and out of hospital, calculated by subtracting the number of days spent in hospital, from time of randomization to end of follow-up (180 days) for each patient
Time frame: up to 7 days
Cardiac power index
Time frame: up to 7 days
Lactate clearence
Time frame: up to 7 days
Pulmonary artery pulsatility index
Time frame: up to 30 days
Number of Participants with acute kidney injury or need for dialysis
Time frame: up to 30 days
Rate of bleeding complications during admission
Time frame: During procedure
Syntax score ( a grading system that evaluates the complexity and prognosis of patients undergoing percutaneous coronary intervention, higher scores denotes more complex disase and higher risk)
Contact information is provided by the study sponsor or research team.
Shenzhen Core Medical Technology CO.,LTD.
Industry
Effects of CorVad Percutaneous Mechanical Circulatory Support in Patients with ST Segment Elevation Myocardial Infarction Complicated by Cardiogenic Shock.
Acronym: Corvad AMICS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07687017
Acute Myocardial Infarction (AMI), Cardiogenic Shock
Leipzig, Saxony, Germany
View Trial DetailsNCT07601828
Cardiogenic Shock, Cardiovascular Diseases
View Trial DetailsNCT07583446
Cardiogenic Shock, Cardiovascular Diseases
View Trial DetailsNCT07580781
Agnosia, Analgesia
London, United Kingdom
View Trial Details